PRESS RELEASE

PRESS RELEASE

February 19, 2025

Abion receives approval from Ministry of Food and Drug Safety for change to phase 2 clinical trial of anticancer drug candidate ‘vabametkib’

Clinical trial of 'lazertinib' and 'vabametkib' combination: "Aiming to develop innovative new drugs"   Abion…

abion_admin_master 0

Love0

PRESS RELEASE

December 30, 2024

Abion’s c-MET targeted anticancer drug: Phase 2 change approved by FDA, Lazertinib combination kicks off

Abion announced on December 27 that the U.S. Food and Drug Administration (FDA) approved modifications…

abion_admin_master 0

Love0

PRESS RELEASE

December 19, 2024

Abion will participate in JPM-Related ‘Biotech Showcase’ and ‘Bio Partnering’ Events

"Partnering with global pharmaceutical and biotech companies offers an opportunity to build new networks"  …

abion_admin_master 0

Love0

PRESS RELEASE

December 10, 2024

[SITC 2024] Abion presents data on antibody-interferon platform for cancer treatment

HOUSTON, TX -- By Lee Han-soo/Korea Biomedical Review correspondent -- A promising new cancer treatment platform…

abion_admin_master 0

Love0

PRESS RELEASE

November 8, 2024

Abion’s ‘Vabametkib’ NSCLC Phase 1 CSR receives safety confirmation, Phase 2 progressing smoothly

Abion revealed on November 6 that it received the phase 1 Clinical Study Report (CSR)…

abion_admin_master 0

Love0

PRESS RELEASE

October 16, 2024

Abion CEO Shin Young Kee “Vabametkib and Lazertinib combination cohort filling for 3Q”

- Combination strategy unveiled at ASCO: “Safety confirmed, Cohort 2 to launch in H2 2024”…

abion_admin_master 0

Love0

PRESS RELEASE

October 16, 2024

ABION Vice President Choi Jun-young: “AI-enhanced MET CTC test ensures fast and accurate lung cancer screening”

- "Application of liquid biopsy and AI in clinical trials for 'vabametkib + lazertinib' combination…

abion_admin_master 0

Love0

PRESS RELEASE

September 24, 2024

ABION, Inc. to Speak at ACCESS CHINA Partnering Forum

September 23rd, 2024 (Shanghai) — We are glad to announce that Hong Seok Choi, Business Development…

abion_admin_master

Love0

PRESS RELEASE

June 28, 2024

Abion signed agreement with Johnson & Johnson on drug supply for combination clinical trial

Abion and Janssen Research and Development, LLC, a Johnson & Johnson company have entered into…

abion_admin_master 0

Love0

PRESS RELEASE

October 16, 2023

With positive phase II interim data in NSCLC, Abion to advance MET-TKI to combo trial

With positive phase II interim data in NSCLC, Abion to advance MET-TKI to combo trial…

abion_admin_master

Love0